Genetic Testing May Add Confusion to Treatment DecisionsNovember 23rd 2015
As genetic testing becomes increasingly available, there will be a growing gap between the wide availability of testing and the relative importance of results to treatment decisions. In the current environment, there's more promise in precision medicine than practical applications in the exam room.
Few Women Receive Genetic Counseling Before BRCA TestingOctober 8th 2015
Genetic counseling before BRCA genetic testing improves patient knowledge, understanding, and satisfaction. However, a new analysis has found that most women undergoing BRCA genetic testing did not receive counseling prior to testing, despite national guidelines and recommendations.
BRCA Mutations in Young Black Women Higher Than ExpectedSeptember 3rd 2015
Young black women have a higher prevalence of BRCA mutations compared with that previously reported among non-Hispanic white women, placing these women at a higher risk for breast and ovarian cancer.
Alice S. Kerber on Discussing Cancer Genetics With PatientsJune 9th 2015
Alice S. Kerber, MN, APRN, ACNS-BC, AOCN, APNG, Oncology Nurse Specialist, Georgia Center for Oncology Research and Education, provides advice on discussing cancer genetics with patients.
An Unmet Need-Discussing Genetic Risk May Benefit All Patients With Breast CancerApril 9th 2015
Many women who are diagnosed with breast cancer are concerned about the genetic risk of developing other cancers themselves or of a loved one developing cancer. However, a large amount of those concerns are not being addressed, according to a new study.
Not "One-Size Fits All"-Jolie Pitt's Story Spotlights Hereditary Cancer RisksApril 8th 2015
Angelina Jolie Pitt recently added another chapter to her BRCA mutation story, making public her choice to undergo a preventive salpingo-oophorectomy, removal of her ovaries and fallopian tubes to reduce her risk of cancer.
Studies Yield More Insight Into Olaparib's Role in Ovarian CancerApril 2nd 2015
Analyses of clinical trials continue to illuminate the role of the PARP inhibitor olaparib (Lynparza) in the treatment of women with ovarian cancer, Ursula A. Matulonis, MD, explained during a plenary session at the 2015 Society of Gynecologic Oncology's Annual Meeting on Women's Cancer.
Dr. Hirshfield Discusses Screening Patients for Genetic MutationsMarch 30th 2015
Kim M. Hirshfield, MD, PhD, medical oncologist, Stacy Goldstein Breast Cancer Center, Rutgers Cancer Institute of New Jersey, discusses selecting individuals to screen for genetic mutations and the challenges of better selecting patients to screen.
Momentum Builds for National Plan for Precision MedicineJanuary 30th 2015
During President Barack Obama's State of the Union Address last week, he announced a nationwide Precision Medicine Initiative that would help cure diseases such as cancer and diabetes. This morning he built on his announcement and outlined a $215 million plan to help develop precision medicine nationwide.
Joan Lunden and Dr Patrick Borgen Discuss Imaging and Genetic Testing in Breast CancerJanuary 22nd 2015
Joan Lunden talks about imaging technology and genetic testing for the early detection of breast cancer with Roy Firestone and Patrick I. Borgen, MD, in advance of her keynote address at the 32nd Miami Breast Cancer Conference (MBCC).
Investigators Find Potential Genetic Clues to Disparities in Colon CancerJanuary 13th 2015
Researchers from the Case Comprehensive Cancer Center have discovered new gene mutations that are unique to colon cancer in African American patients, who have the highest incidence and death rate from the disease.
Update on BRCA1/2: Technical and Policy Questions Arise as Testing Options ExpandJanuary 2nd 2015
As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing. In the past 18 months, the floodgates for testing options have opened, as companies seek to enter the diagnostic market in the wake of the US Supreme Court's June 2013 ruling that "naturally occurring" human genes are a "product of nature" and cannot be patented, breaking Myriad Genetics' monopoly on BRCA1/2 gene testing.
Olaparib Gets Approval for BRCA-Mutated Advanced Ovarian CancerDecember 20th 2014
The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer. The approval was based on results from a single-arm phase II study of patients with deleterious or suspected deleterious germline BRCA-mutated advanced cancers
Dr. Chagpar Discusses Patient Perceptions of Genetic Testing's Impact on Health InsuranceDecember 19th 2014
Anees B. Chagpar, MD, MSc, MA, MPH, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, program director, Interdisciplinary Breast Fellowship, assistant director, Diversity and Health Equity at Yale Cancer Center, discusses a study that looked at patient perceptions of the impact of genetic testing for breast cancer risk on health insurance.